8-Sep-2026
Globe Newswire (Thu, 27-Aug 4:05 PM ET)
Globe Newswire (Thu, 27-Aug 9:01 AM ET)
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
ACCESS Newswire (Thu, 27-Aug 9:01 AM ET)
Globe Newswire (Fri, 14-Aug 7:15 AM ET)
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
Globe Newswire (Wed, 12-Aug 9:45 PM ET)
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Globe Newswire (Wed, 12-Aug 4:01 PM ET)
Globe Newswire (Thu, 6-Aug 8:45 AM ET)
Globe Newswire (Fri, 24-Jul 2:40 PM ET)
Market Chameleon (Tue, 16-Jun 7:06 AM ET)
Globe Newswire (Tue, 16-Jun 8:02 AM ET)
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics trades on the NASDAQ stock market under the symbol OTLK.
As of September 8, 2026, OTLK stock price declined to $0.64 with 4,595,567 million shares trading.
OTLK has a beta of 2.91, meaning it tends to be more sensitive to market movements. OTLK has a correlation of 0.04 to the broad based SPY ETF.
OTLK has a market cap of $155.43 million. This is considered a Micro Cap stock.
Last quarter Outlook Therapeutics reported $9,000 in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.01.
In the last 3 years, OTLK traded as high as $18.00 and as low as $.16.
The top ETF exchange traded funds that OTLK belongs to (by Net Assets): VTI, VXF.
OTLK has underperformed the market in the last year with a price return of -27.9% while the SPY ETF gained +19.2%. OTLK has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.4% and -1.0%, respectively, while the SPY returned +1.4% and 0.0%, respectively.
OTLK support price is $.63 and resistance is $.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OTLK shares will trade within this expected range on the day.
